Profit Investment Management LLC Makes New Investment in Bristol-Myers Squibb Co (NYSE:BMY)

Share on StockTwits

Profit Investment Management LLC acquired a new position in Bristol-Myers Squibb Co (NYSE:BMY) in the 4th quarter, HoldingsChannel reports. The fund acquired 10,070 shares of the biopharmaceutical company’s stock, valued at approximately $646,000.

Several other large investors have also made changes to their positions in the business. Puzo Michael J increased its stake in Bristol-Myers Squibb by 7.8% in the fourth quarter. Puzo Michael J now owns 11,381 shares of the biopharmaceutical company’s stock worth $732,000 after purchasing an additional 821 shares during the period. Somerville Kurt F boosted its stake in shares of Bristol-Myers Squibb by 23.6% during the fourth quarter. Somerville Kurt F now owns 10,445 shares of the biopharmaceutical company’s stock valued at $670,000 after purchasing an additional 1,995 shares during the period. Viking Fund Management LLC grew its holdings in shares of Bristol-Myers Squibb by 40.6% in the fourth quarter. Viking Fund Management LLC now owns 45,000 shares of the biopharmaceutical company’s stock worth $2,889,000 after purchasing an additional 13,000 shares during the last quarter. Cardinal Capital Management Inc. grew its holdings in shares of Bristol-Myers Squibb by 5.7% in the fourth quarter. Cardinal Capital Management Inc. now owns 13,850 shares of the biopharmaceutical company’s stock worth $889,000 after purchasing an additional 750 shares during the last quarter. Finally, FormulaFolio Investments LLC grew its holdings in shares of Bristol-Myers Squibb by 22.4% in the fourth quarter. FormulaFolio Investments LLC now owns 8,773 shares of the biopharmaceutical company’s stock worth $563,000 after purchasing an additional 1,605 shares during the last quarter. Institutional investors and hedge funds own 83.02% of the company’s stock.

In other news, insider Louis S. Schmukler sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total value of $1,414,000.00. Following the sale, the insider now directly owns 31,963 shares in the company, valued at approximately $1,807,827.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP John E. Elicker sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total transaction of $849,900.00. Following the completion of the sale, the senior vice president now owns 74,471 shares in the company, valued at $4,219,526.86. The disclosure for this sale can be found here. 0.13% of the stock is owned by corporate insiders.

NYSE BMY opened at $66.58 on Thursday. Bristol-Myers Squibb Co has a one year low of $42.48 and a one year high of $67.09. The company has a debt-to-equity ratio of 1.37, a quick ratio of 3.72 and a current ratio of 3.83. The company has a market capitalization of $108.25 billion, a price-to-earnings ratio of 16.73, a price-to-earnings-growth ratio of 0.85 and a beta of 0.73. The company’s 50-day simple moving average is $62.52 and its two-hundred day simple moving average is $53.03.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.11. The firm had revenue of $6.01 billion for the quarter, compared to the consensus estimate of $5.89 billion. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The company’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period last year, the firm earned $1.09 earnings per share. Equities analysts expect that Bristol-Myers Squibb Co will post 4.47 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be issued a dividend of $0.45 per share. The ex-dividend date is Thursday, January 2nd. This represents a $1.80 dividend on an annualized basis and a yield of 2.70%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. Bristol-Myers Squibb’s dividend payout ratio is currently 45.23%.

BMY has been the subject of a number of research analyst reports. UBS Group lifted their price objective on shares of Bristol-Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a report on Wednesday, October 23rd. Mizuho initiated coverage on shares of Bristol-Myers Squibb in a research note on Monday, November 25th. They issued a “buy” rating on the stock. Wolfe Research set a $66.00 target price on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Friday, November 1st. Gabelli started coverage on shares of Bristol-Myers Squibb in a research note on Wednesday, November 27th. They set a “buy” rating for the company. Finally, Bank of America assumed coverage on shares of Bristol-Myers Squibb in a research note on Wednesday, October 16th. They set a “buy” rating and a $60.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Buy” and a consensus price target of $61.69.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Inverted Yield Curve

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.